1. Introduction and Background
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic, metabolically stabilised derivative of angiotensin IV (Ang IV), a hexapeptide fragment of the renin-angiotensin system (RAS). Although the RAS is principally recognised for its role in cardiovascular homeostasis through the regulation of blood pressure, fluid balance, and electrolyte composition, research conducted over the past three decades has identified a parallel brain-resident RAS with functions that extend well beyond haemodynamic control. Of particular relevance to neuroscience is angiotensin IV (Val-Tyr-Ile-His-Pro-Phe), the 3-8 fragment of angiotensin II, which binds selectively to the AT4 receptor subtype and has been implicated in the facilitation of learning and memory processes across a range of preclinical paradigms (Wright and Harding, 1995).
The identification of the AT4 receptor as insulin-regulated aminopeptidase (IRAP) by Albiston et al. (2001) represented a significant advance in understanding the molecular pharmacology of angiotensin IV. IRAP is a type II transmembrane protein of the M1 aminopeptidase family that is co-localised with the glucose transporter GLUT4 in specialised vesicles within hippocampal neurons and other cell types. Angiotensin IV was shown to function as a competitive inhibitor of IRAP's catalytic activity, and this inhibition was initially proposed as the mechanism underpinning the procognitive effects of AT4 receptor ligands (Albiston et al., 2001). However, the native hexapeptide suffers from rapid enzymatic degradation by aminopeptidases and endopeptidases in both plasma and brain tissue, resulting in a biological half-life of the order of seconds to minutes, thereby severely constraining its pharmacological utility (Wright and Harding, 2008).
Dihexa was designed by the laboratory of Joseph Harding and John Wright at Washington State University as part of a systematic programme to develop angiotensin IV analogues with enhanced metabolic stability and oral bioavailability. Through iterative modification of the parent hexapeptide structure, the researchers replaced susceptible peptide bonds with non-hydrolysable surrogates and introduced the N-terminal hexanoic acid cap, yielding a compound with markedly improved resistance to enzymatic degradation while retaining, and indeed substantially augmenting, the procognitive properties of the parent molecule .
2. Mechanism of Action: HGF/MET Receptor System Potentiation
2.1 From AT4/IRAP to the Hepatocyte Growth Factor Paradigm
Although the initial pharmacological characterisation of Dihexa proceeded within the framework of AT4 receptor/IRAP inhibition, subsequent research from the Wright and Harding laboratory fundamentally revised the mechanistic understanding of the compound's activity. Through a series of experiments employing pharmacological antagonism, receptor knockdown, and binding assays, the group demonstrated that the procognitive and synaptogenic effects of Dihexa and related angiotensin IV analogues are not dependent upon IRAP inhibition, but rather upon potentiation of signalling through the hepatocyte growth factor (HGF)/c-Met receptor tyrosine kinase system (Benoist et al., 2011).
Hepatocyte growth factor, also designated scatter factor, is a pleiotropic cytokine that signals through the c-Met receptor tyrosine kinase (also referred to simply as MET). The HGF/MET system is essential during embryonic development for the morphogenesis of multiple organ systems, and in the adult central nervous system it functions as a critical mediator of neuronal survival, neurite outgrowth, dendritic branching, and synaptic plasticity. Wright and Harding (2015) proposed that Dihexa acts as an allosteric potentiator of the HGF/MET interaction, binding at or near the MET receptor and facilitating a conformational state that enhances HGF-induced receptor dimerisation and autophosphorylation. Crucially, Dihexa does not activate MET in the absence of HGF; rather, it amplifies the signalling output of endogenous ligand-receptor engagement, a mechanism analogous to that of positive allosteric modulators at ligand-gated ion channels (Wright and Harding, 2015).
2.2 Synaptogenesis and Dendritic Spine Formation
The downstream consequences of HGF/MET potentiation by Dihexa are particularly relevant to synaptic connectivity. Benoist et al. (2011) reported that activation of the MET receptor system in cultured hippocampal neurons resulted in a statistically significant increase in the density of dendritic spines, the small protrusions from neuronal dendrites that serve as the postsynaptic sites for the majority of excitatory synapses in the mammalian brain. Dendritic spine density is widely regarded as a structural correlate of synaptic strength and is positively associated with learning capacity and memory consolidation in both rodent and primate models. Furthermore, the loss of dendritic spines in hippocampal and cortical regions constitutes one of the earliest and most consistent neuropathological features observed in neurodegenerative conditions characterised by progressive cognitive decline (Benoist et al., 2011).
The synaptogenic action of Dihexa appears to proceed through the canonical MET signalling cascade, involving receptor autophosphorylation, recruitment of the adaptor proteins GAB1 and GRB2, and subsequent activation of the PI3K/Akt and Ras/MAPK/ERK pathways. Both of these intracellular cascades converge on transcriptional programmes and local translational machinery that regulate the synthesis of synaptic structural proteins, including PSD-95, synaptophysin, and components of the AMPA receptor complex. The finding that the synaptogenic effects of Dihexa were abolished by the selective MET kinase inhibitor SU11274 and by siRNA knockdown of MET provided direct confirmation that these effects are mediated through the HGF/MET axis rather than through an alternative target (Benoist et al., 2011).
3. Cognitive Research: Preclinical Evidence
3.1 The Scopolamine Impairment Model
The scopolamine-induced amnesia model represents one of the most widely employed paradigms for the preclinical evaluation of procognitive compounds. Scopolamine, a muscarinic acetylcholine receptor antagonist, produces dose-dependent deficits in the acquisition and retention of spatial and associative memory tasks in rodents, thereby modelling the cholinergic hypofunction that is a hallmark of Alzheimer's disease neuropathology. McCoy et al. (2013) evaluated Dihexa and a series of related angiotensin IV analogues in rats rendered amnestic by scopolamine administration. In the Morris water maze, a spatial navigation task that is critically dependent upon hippocampal integrity, scopolamine-treated rats receiving Dihexa demonstrated a statistically significant reduction in escape latency and increased time spent in the target quadrant during probe trials relative to scopolamine-only controls. Notably, Dihexa was effective at oral doses in the low microgram-per-kilogram range, representing a potency enhancement of approximately seven orders of magnitude relative to the parent compound angiotensin IV .
3.2 Spatial Learning and Memory Consolidation
Beyond the pharmacological impairment model, Dihexa has been evaluated in cognitively intact aged animals, a paradigm that more closely approximates the gradual cognitive decline associated with normal ageing. Wright et al. (2012) reported that aged rats (approximately 24 months) treated with Dihexa exhibited improvements in spatial learning acquisition in the Morris water maze that were comparable in magnitude to the performance levels of young adult controls. The compound also facilitated memory consolidation as assessed by 24-hour and 72-hour retention probe trials, suggesting effects on both the encoding and stabilisation phases of hippocampus-dependent memory .
Kawas et al. (2011) presented further data demonstrating that Dihexa augmented hippocampal long-term potentiation (LTP) in acute brain slice preparations, a cellular electrophysiological correlate of synaptic plasticity that is widely regarded as the molecular substrate of learning and memory. The enhancement of LTP amplitude and duration was consistent with the structural synaptogenic effects described above and provided an electrophysiological mechanism linking the molecular pharmacology of Dihexa to its behavioural procognitive effects (Kawas et al., 2011).
4. Blood-Brain Barrier Penetration
A critical determinant of the translational potential of any centrally acting compound is its capacity to traverse the blood-brain barrier (BBB), the highly selective endothelial barrier that restricts the passage of hydrophilic and large-molecular-weight substances from the systemic circulation into the brain parenchyma. Peptide therapeutics have historically been constrained by poor BBB permeability, which has limited the development of neuropeptide-based pharmacotherapies despite the abundance of neuropeptide targets in the central nervous system.
The molecular design of Dihexa specifically addressed this limitation. The replacement of polar peptide bonds with lipophilic non-hydrolysable linkers and the incorporation of the N-terminal hexanoic acid moiety confer a degree of amphiphilicity that facilitates passive transcellular diffusion across the BBB endothelium. McCoy et al. (2013) reported that Dihexa achieved pharmacologically relevant concentrations in rat brain tissue following oral administration, as inferred from the compound's efficacy in behavioural paradigms at oral doses that would be insufficient were the compound excluded from the central compartment. This observation was corroborated by direct measurement of radiolabelled Dihexa distribution, which confirmed accumulation in hippocampal and cortical regions following systemic administration .
The oral bioavailability and BBB permeability of Dihexa distinguish it from the majority of peptide-derived research compounds and represent a substantial pharmacokinetic advantage relative to both the parent molecule angiotensin IV and earlier AT4 receptor ligands such as Nle1-Ang IV, which require central (intracerebroventricular) administration to produce procognitive effects (Wright and Harding, 2008).
5. Current Research Directions
Contemporary research on Dihexa and the broader HGF/MET potentiator class proceeds along several axes. First, the mechanism of allosteric potentiation at the MET receptor remains incompletely characterised at the structural level. Whilst pharmacological and genetic evidence firmly establishes the dependence of Dihexa's effects on MET signalling, the precise binding site and the conformational changes induced in the receptor ectodomain have yet to be elucidated through crystallographic or cryo-electron microscopy studies. Resolution of this question would facilitate rational structure-activity relationship optimisation and the development of second-generation compounds with enhanced selectivity and potency profiles (Wright and Harding, 2015).
Second, the relationship between HGF/MET signalling and other neurotrophic factor systems in the context of neurodegeneration represents an active area of investigation. HGF and brain-derived neurotrophic factor (BDNF) share overlapping downstream signalling pathways, particularly through the PI3K/Akt survival cascade, raising the question of whether MET potentiation may produce synergistic neuroprotective effects in combination with strategies that augment BDNF/TrkB signalling. Wright and Harding (2019) have discussed the potential for combinatorial approaches targeting multiple neurotrophic systems as a strategy for achieving more robust and durable cognitive benefits than can be obtained through single-target interventions (Wright and Harding, 2019).
Third, the safety pharmacology and long-term tolerability of sustained HGF/MET potentiation remain to be systematically evaluated. The MET receptor is an established proto-oncogene, and activating mutations in MET or overexpression of HGF are associated with tumorigenesis in several tissue types. The distinction between allosteric potentiation of endogenous HGF signalling (as produced by Dihexa) and constitutive receptor activation (as occurs in oncogenic MET mutations) is mechanistically significant, but the long-term consequences of pharmacological MET potentiation for cellular proliferation and transformation risk require rigorous preclinical characterisation before clinical evaluation can be contemplated (Wright and Harding, 2015).
6. Conclusion
Dihexa represents a novel pharmacological approach to the modulation of synaptic plasticity through potentiation of the HGF/MET receptor tyrosine kinase system. Originating from systematic structure-activity studies on the angiotensin IV hexapeptide, it has progressed from an AT4/IRAP ligand to a mechanistically distinct compound whose procognitive effects are mediated through facilitation of neurotrophic factor signalling. Preclinical evidence demonstrates that Dihexa promotes synaptogenesis and dendritic spine formation in hippocampal neurons, reverses scopolamine-induced cognitive impairment, ameliorates age-related spatial learning deficits, and enhances hippocampal long-term potentiation, all at remarkably low oral doses that are consistent with efficient blood-brain barrier penetration. The compound's unique mechanism of action, combined with its favourable pharmacokinetic properties, has positioned it as a subject of continued investigation within the neuropharmacology research community. However, important questions regarding the structural basis of MET potentiation and the long-term safety implications of sustained HGF/MET system augmentation remain to be addressed through further preclinical and translational studies.